Targeting the gastrin-releasing peptide receptor (GRPR)with thebombesin analogue RM26, a 9 aa peptide, has been a promising strategyfor cancer theranostics, with recent success in radionuclide imagingof prostate cancer. This evidence concerns the gene GRPR and cancer.